Skip to main content
You have permission to edit this article.

Diabetes Management app, Klinio, is Selected by Insurance Provider, Cigna, as 2021 Cigna Innovation Challenge Finalist

By: IssueWire
Klinio Logo

Healthcare and insurance provider, Cigna, names the diabetes management app, Klinio, a finalist for their 2021 Cigna Innovation Challenge.

New York City, New York Dec 14, 2021 ( - The healthcare and insurance provider, Cigna, has named the diabetes management app, Klinio, as a finalist for their 2021 Cigna Innovation Challenge.

Nutritionists, physicians, and fitness professionals collaborated on Klinio, creating a personalized and science-based solution for managing diabetes and prediabetes. 

Klinio is a personalized diabetes tracker and management app that helps patients improve their condition by providing meal plans, monitoring their carb intake, and recommending healthy recipes to better manage and track their weight and glucose levels. Klinio stands out from other diabetes apps with its holistic approach that helps build long-lasting behavior change. 

Cigna is partnering with the innovation hub and incubator, MATTER, to identify three industry leaders who are transforming diabetes solutions. 

Dr. Braden Barnett, Endocrinologist and Medical Advisor to Klinio, said this recognition by Cigna and MATTER will give Klinio more resources for clinical research, new content while creating a better user experience with the app that provides better outcomes for patients.

"Cigna is a healthcare giant and MATTER is notorious for identifying the best health tech startups that are creating change, so getting recognized by them reinforces how Klinio is making a difference for all patients battling diabetes," said Barnett. "Across medicine - regardless of specialty - we can all improve outcomes faster when we work together to find solutions."

Dr. Jeffrey Klein, a medical executive at Cigna and an innovation challenge mentor, said the goal of the accelerator program is to create new pilot opportunities with Cigna.

"Providing mentorship to these companies is one way that Cigna can help to rapidly advance new ideas in the diabetes space," said Klein. "As a physician, I recognize many of the factors affecting diabetes, especially how social and behavioral health drivers contribute to how people manage their care. It's exciting to work with entrepreneurs looking to make positive changes in this arena."

Other finalists for the 2021 Cigna Innovation Challenge include:

GlucosePATH - helps patients find affordable and effective treatments for Type 2 Diabetes.

Neap - a mindful diabetes management platform that uses psychologist-approved techniques to help with diabetes-related stress. 

Pack Health - an evidence-based patient engagement platform that changes health behaviors to close gaps in care and improve outcomes like addressing chronic conditions, comorbidities, and social determinants. 

SNAQ - helps people living with diabetes take the guesswork out of mealtime decisions. 

Viora Health - HIPAA-compliant solution leverages data, behavioral science, and community-based resources to proactively address health inequities perpetuated by social and behavioral determinants before they result in disease progression and episodic costs.

About Klinio - Diabetes Management App

Nutritionists, physicians, and fitness professionals collaborated on Klinio, to create a personalized and engaging program. The independent organization, Validation Institute, recently validated findings by Kilo Health that found patients with type-2 diabetes who used Klinio for a minimum of 19 days over 2.5 months were twice as likely to reduce their absolute HbA1c value by 0.59 percent.

The data also found users were twice as likely to achieve clinically meaningful improvement than users who had fewer logins. A change of 0.5 is considered a meaningful change in a person's health status and is accepted by the Food and Drug Administration.  

Media Contact

Mark Macias


Source :Klinio

This article was originally published by IssueWire. Read the original article here.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.